Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications
- Autores
- Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; Cardinali, Daniel Pedro; Hardeland, Rüdiger
- Año de publicación
- 2011
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.
Fil: Pandi Perumal, Seithikurippu R.. College Street; Canadá
Fil: Spence, David Warren. No especifíca;
Fil: Verster, Joris C.. University of Utrecht; Países Bajos
Fil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; India
Fil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; Canadá
Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina
Fil: Hardeland, Rüdiger. University of Goettingen; Alemania - Materia
-
CIRCADIAN RHYTHMS
HYPNOTIC
INSOMNIA
MELATONIN
RAMELTEON
SLEEP - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/192218
Ver los metadatos del registro completo
id |
CONICETDig_917002c3162d4511b3f26949b55dacb7 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/192218 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical ApplicationsPandi Perumal, Seithikurippu R.Spence, David WarrenVerster, Joris C.Srinivasan, VenkatramanujamBrown, Gregory M.Cardinali, Daniel PedroHardeland, RüdigerCIRCADIAN RHYTHMSHYPNOTICINSOMNIAMELATONINRAMELTEONSLEEPhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only.Fil: Pandi Perumal, Seithikurippu R.. College Street; CanadáFil: Spence, David Warren. No especifíca;Fil: Verster, Joris C.. University of Utrecht; Países BajosFil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; IndiaFil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; CanadáFil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; ArgentinaFil: Hardeland, Rüdiger. University of Goettingen; AlemaniaSAGE Publications2011-04info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/192218Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-651179-5735CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.4137/JCNSD.S1611info:eu-repo/semantics/altIdentifier/doi/10.4137/JCNSD.S1611info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T10:00:58Zoai:ri.conicet.gov.ar:11336/192218instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 10:00:59.205CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
title |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
spellingShingle |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications Pandi Perumal, Seithikurippu R. CIRCADIAN RHYTHMS HYPNOTIC INSOMNIA MELATONIN RAMELTEON SLEEP |
title_short |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
title_full |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
title_fullStr |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
title_full_unstemmed |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
title_sort |
Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications |
dc.creator.none.fl_str_mv |
Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkatramanujam Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger |
author |
Pandi Perumal, Seithikurippu R. |
author_facet |
Pandi Perumal, Seithikurippu R. Spence, David Warren Verster, Joris C. Srinivasan, Venkatramanujam Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger |
author_role |
author |
author2 |
Spence, David Warren Verster, Joris C. Srinivasan, Venkatramanujam Brown, Gregory M. Cardinali, Daniel Pedro Hardeland, Rüdiger |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
CIRCADIAN RHYTHMS HYPNOTIC INSOMNIA MELATONIN RAMELTEON SLEEP |
topic |
CIRCADIAN RHYTHMS HYPNOTIC INSOMNIA MELATONIN RAMELTEON SLEEP |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only. Fil: Pandi Perumal, Seithikurippu R.. College Street; Canadá Fil: Spence, David Warren. No especifíca; Fil: Verster, Joris C.. University of Utrecht; Países Bajos Fil: Srinivasan, Venkatramanujam. Sri Sathya Sai Medical Educational and Research Foundation; India Fil: Brown, Gregory M.. University of Toronto; Canadá. Centre for Addiction and Mental Health; Canadá Fil: Cardinali, Daniel Pedro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Pontificia Universidad Católica Argentina "Santa María de los Buenos Aires". Facultad de Ciencias Médicas. Departamento de Docencia e Investigación; Argentina. Universidad de Buenos Aires. Facultad de Medicina; Argentina Fil: Hardeland, Rüdiger. University of Goettingen; Alemania |
description |
Ramelteon is a tricyclic synthetic analog of melatonin that acts specifically on MT1 and MT2 melatonin receptors. Ramelteon is the first melatonin receptor agonist approved by the Food and Drug Administration (FDA) for the treatment of insomnia characterized by sleep onset difficulties. Ramelteon is both a chronobiotic and a hypnotic that has been shown to promote sleep initiation and maintenance in various preclinical and in clinical trials. The efficacy and safety of ramelteon in patients with chronic insomnia was initially confirmed in short-term placebo-controlled trials. These showed little evidence of next-day residual effects, withdrawal symptoms or rebound insomnia. Other studies indicated that ramelteon lacked abuse potential and had a minimal risk of producing dependence or adverse effects on cognitive or psychomotor performance. A 6-month placebo-controlled international study and a 1-year open-label study in the USA demonstrated that ramelteon was effective and well tolerated. Other potential off-label uses of ramelteon include circadian rhythm sleep disorders such as shift-work and jet lag. At the present time the drug should be cautiously prescribed for short- term treatment only. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-04 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/192218 Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-65 1179-5735 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/192218 |
identifier_str_mv |
Pandi Perumal, Seithikurippu R.; Spence, David Warren; Verster, Joris C.; Srinivasan, Venkatramanujam; Brown, Gregory M.; et al.; Pharmacotherapy of Insomnia with Ramelteon: Safety, Efficacy and Clinical Applications; SAGE Publications; Journal of Central Nervous System Disease; 3; 4-2011; 51-65 1179-5735 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/https://journals.sagepub.com/doi/10.4137/JCNSD.S1611 info:eu-repo/semantics/altIdentifier/doi/10.4137/JCNSD.S1611 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
SAGE Publications |
publisher.none.fl_str_mv |
SAGE Publications |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842269668949098496 |
score |
13.13397 |